In the subgroup analysis of cancer type, COMT Val158Met was significantly associated with increased risks of bladder cancer in recessive model, and esophageal cancer in homozygote model, heterozygote model, and dominant model. Subgroup analyses based on ethnicities, COMT Val158Met was significantly associated with increased risk of cancer in homozygote and recessive model among Asians. In addition, homozygote, recessive, and dominant models were significantly associated with increased cancer risk in the subgroup of allele-specific polymerase chain reaction genotyping. Significant associations were not observed when data were stratified by the source of the controls. In summary, this meta-analysis suggested that COMT Val158Met polymorphism might not be a risk factor for overall cancer risk, but it might be involved in cancer development at least in some ethnic groups (Asian) or some specific cancer types (bladder and esophageal cell cancer). Further evaluations of more preclinical and epidemiological studies are required.
Introduction
Cancer constitutes an enormous burden on the society in more and less economically developed countries alike.
1,2 Based on GLOBOCAN estimates, ~14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. 1 According to the development trend, the new cases in 2030 will reach 22.2 million. 2 It is well known that the etiology and development of cancer are as a result of complex interactions between genetic and environmental factors. 3 Genes determine the susceptibility of individual to environment, and environmental factors often damage the DNA in turn. Recent studies have shown that host genetic factors are closely related to the pathophysiology of many human cancers. 4 The most common form of genetic variation, that is, single-nucleotide polymorphisms, is known to contribute individual susceptibility to cancer. 5 Therefore, it is anticipated that the identification of key gene polymorphisms associated with cancer risk is essential for predicting risk of individuals, and that it It is an important enzyme involved in the inactivation of endogenous catecholamine and catechol estrogens. Catechol estrogens have been shown to have the ability to damage DNA and carcinogenetic potential. 7 Therefore, the loss of or changes in COMT is supposed to contribute to genomic instability and tumor genesis. In line with these considerations, it has been hypothesized that COMT Val158Met might influence the development of all cancers. Up to now, many researches have indicated the link between COMT polymorphism and cancer susceptibility. Several polymorphisms have been identified, including the widely studied polymorphism Val158Met(rs4680). 8 This change has been associated with a three-to four-fold decrease in the activity of COMT compared with the wild-type COMT-Val allele. 9, 10 It is biologically reasonable to hypothesize that women who carry mutant COMT-Met allele may have higher cancer risks.
In recent years, many studies have investigated the relationship between COMT Val158Met polymorphism in different races and different types of cancer, but the results were inconclusive or controversial. The inconsistent conclusions may be due to a possible minor effect of the polymorphism on cancer or the small sample size in studies with inadequate statistical power of complex traits. Meta-analysis is a powerful statistical tool to pool different studies to overcome deficiencies such as small sample size and to provide more reliable results. Although some previous meta-analyses have reported the association between COMT Val158Met polymorphism and ovarian cancer (up to eight case-control studies included), 102, 103 breast cancer (up to 56 case-control studies included), 65, [104] [105] [106] [107] [108] endometrial cancer (up to seven case-control studies included), 103, 109, 110 prostate cancer (up to six case-control studies included), [111] [112] [113] and lung cancer (evidence from six case-control studies), 114 only specific cancer types or race populations were included, which led to their limitations. To update the results of previous meta-analyses and to provide a more precise assessment of the association between COMT Val158Met and cancer risk, we performed a comprehensive meta-analysis by including the most recent and relevant articles.
Materials and methods

Identification and eligibility of relevant studies
The meta-analysis was conducted following the criteria of Preferred Reporting Items for Systematic Reviews and Meta Analyses. A comprehensive literature search was performed using the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and EMBASE database for relevant articles published (the last search update was February 15, 2015) with keywords "COMT", "Catechol-O-methyltransferase", "Val158Met", "rs4680", "single nucleotide polymorphism", "polymorphism", "Variant", "Mutation", "Cancer", "tumor", "neoplasm", "malignancy", or "Carcinoma". In addition, studies were identified by a manual search of reviews and retrieved studies. Search results were restricted to human populations, and the articles were written in English or Chinese. We included all the casecontrol studies and cohort studies that have investigated the association between COMT Val158Met polymorphisms and cancer risk with genotyping data. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications. When the same patient population was used in several publications, only the most recent, the largest or the most complete study was included.
assessment of study quality
The quality of the included studies was assessed by the Newcastle-Ottawa Scale (NOS; http://www.ohri.ca/programs/ clinical_epidemiology/oxford.asp), 115 including selection of groups, comparability of groups, and ascertainment of exposure. The NOS score ranges from 0 to 10 stars. Studies with NOS score  five stars were included in the final analysis.
inclusion criteria
All studies were included if they met the following criteria: 1) only the case-control studies or cohort studies were considered, 2) studies that investigated the COMT Val158Met polymorphism and the risk of cancer susceptibility were included, and 3) the genotype distribution of the polymorphism in cases and controls was described in details, and the results were expressed as odds ratio (OR) and corresponding 95% confidence interval (95% CI). Major reasons for exclusion of studies were as follows: 1) not for cancer research, 2) only case population, 3) duplicate of previous publication, and 4) review articles, editorials, case reports, studies with preliminary results not on COMT Val158Met polymorphism or outcome, and investigations of the role of COMT expression related to disease. Ethics approval for the study was granted by the local institute, the People's Hospital of Three Gorges University Ethics Committee.
Data extraction
Using a standardized form, data from published studies were extracted independently by two reviewers to evaluate 
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cOMT Val158Met polymorphism and cancer risk their eligibility for inclusion by first screening the title and abstract of each identified reference and then establishing the eligibility of the included papers based on the full text when necessary. For each included study, the following information was collected: first author, year of publication, region, study design, sample size, source of control, genotyping method, allele or genotype frequencies, and evidence of Hardy-Weinberg equilibrium (HWE). Any discrepancy between the two reviewers was resolved by discussion and consultation with a third reviewer.
statistical analysis
ORs and their 95% CIs were used to determine the strength of association between the COMT Val158Met polymorphism and cancer risk. The significance of the pooled OR was determined using the Z test, and P0.05 was considered statistically significant. Homozygote model (AA vs GG), heterozygote model (GA vs GG), dominant model (GA + AA vs GG), and recessive model (AA vs GG + GA) were investigated. Subgroup analysis was performed by ethnicity, cancer type (if one cancer type contained less than two studies, it was defined as "other"), source of controls, and hospital or population controls. Effective modification by a subgroup was assessed by testing the interaction between genotypes and stratification variables by using logistic regression analyses (random-effects estimator). HWE was tested using the chi-square test among controls, and P0.05 was considered a significant departure from HWE. If the P-value for heterogeneity was 0.05 and I 2 50%, indicating an absence of heterogeneity among studies, the fixed-effects model (the Mantel-Haenszel method) was used. 116 In contrast, if either the P-value for heterogeneity was 0.05 or I 2 was 50%, indicating heterogeneity among the studies, the more appropriate random-effects model (the DerSimonian and Laird method) was used. 117 Sensitivity analyses were performed to assess the stability of the results. Begg's funnel plots were used to diagnose potential publication bias, and P0.05 was used to indicate possible publication bias. 118 All analyses were performed using RevMan 5.3 (updated in March 2012 by the Cochrane Collaboration). P-values were based on two-sided tests.
Results
literature search and meta-analysis databases
Following the searching strategy, 337 potentially relevant studies were retrieved. After title and abstract screening, nine of them were ruled out because of repeated data. A total of 202 irrelevance articles were excluded. In addition, after the full texts of the remaining 182 articles were read, 90 articles were excluded for the following reasons: article was a review (n=27), articles had insufficient data (n=13), articles were not related to cancer (n=34), and articles were not related to COMT (n=16). A total of 92 publications with full text were selected and were subjected to further examination. Because seven studies included more than one ethnicity, genotype method, control source, or tumor type and were performed by the same author, we treated them separately in this metaanalysis. Of those, 99 case-control studies with 43,085 cancer cases and 57,882 control subjects were included in our metaanalysis. A flow chart showing the detailed steps of study selection is shown in Figure 1 . All studies were case-control studies with the following tumor-type distribution: three were conducted for bladder cancer, two for renal cancer, nine for endometrial cancer, eight for ovarian cancer, 62 for breast cancer, six for lung cancer, three for liver cancer, two for colon cancer, two for esophageal cell cancer, one for thyroid cancer and non-Hodgkin lymphoma, and one for testicular germ cell tumor. Fifty studies investigated the risks in Caucasian populations, 35 studies investigated Asian populations, ten studies investigated mixed populations, and the remaining studies were conducted in African populations. Five main genotyping methods were used such as polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), TaqMan, sequencing, matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF), and allele-specific PCR (AS-PCR). By source of controls, 50 studies were population based, 45 studies were hospital based, and four studies were not clear. The distribution of the genotypes in the control subjects was in agreement with HWE, except for eight studies. 34, 37, 70, 72, 80, 88, 95, 119 The quality assessment showed that the quality scores ranged from 5 to 9 with a median score of 6, suggesting that all studies were of high quality. The main characteristics of the eligible studies are listed in Table 1 .
Quantitative synthesis
Overall, no significant associations between COMT Val158Met and cancer risk were found using homozygote model ( with increased cancer risk in the subgroup of AS-PCR genotyping method, but no significant associations were observed when PCR-RFLP, TaqMan, sequencing, MALDI-TOF, and other genotyping method were used. No significant associations were detected when the studies were stratified on the basis of the source of control subjects.
Test of heterogeneity and sensitivity
Heterogeneity among studies was observed in the overall comparisons as well as in the subgroup analyses. The source of heterogeneity was investigated by cancer ethnicity (European, Asian, African, and mixed; P=0.483), cancer types (bladder, breast, renal, endometrial, lung, liver, ovarian, colon, and other cancer types; P=0.684), control source (population based, hospital based, and family based; P=0.659), and genotyping method (AS-PCR, PCR-RFLP, TaqMan, sequencing, MALDI-TOF, and other genotyping method; P=0.647) using meta-regression, but no covariables were found to contribute to the heterogeneity. Abbreviations: hWe, hardy-Weinberg equilibrium; nOs, newcastle-Ottawa scale; hB, hospital based; Pcr-rFlP, polymerase chain reaction-restriction fragment length polymorphism; PB, population based; Dash, dynamic allelespecific hybridization; FB, family based; NA, not available; MALDI-TOF, matrix-assisted laser desorption ionization time of flight mass spectrometry; NHL, non-Hodgkin lymphoma; TGCT, testicular germ cell tumor; AS-PCR, allelespecific PCR; LP, Luorescence polarization; NR, not reported.
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Zhou et al Sensitivity analysis was conducted to verify the effect of each study on the overall OR by repeating the meta-analysis, but one study was omitted each time. When sensitivity analyses were performed without HWE violating studies, all the results were not materially altered. The results showed that the pooled ORs of these three polymorphisms were not materially altered by the contribution of any individual study, thus confirming that the results of this meta-analysis were statistically robust.
Publication bias
Begg's funnel plot and Egger's test were performed to evaluate the publication bias of the studies. The shape of the funnel plots showed that the dots were almost symmetrically distributed and were predominantly in 95% confidence limits (dominant model, Figure 2 ). The results of Egger's test statistically confirmed the absence of publication bias in the dominant model (t=1.68, P=0.096).
Discussion
In the past several years, interest in the genetic susceptibility to cancers has drawn increased attention to the studies on polymorphisms of genes involved in tumor genesis. Genome-wide association study, also known as whole genome association study, is widely used in the study of genetic epidemiology. At present, 1,369 susceptibility loci associated with cancer risk have been identified by 
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cOMT Val158Met polymorphism and cancer risk genome-wide association study, but none of these studies had reported significant associations between cancer susceptibility and COMT Val158Met polymorphisms. We searched the manufacturers' websites (http://www.affymetrix.com/index.affx and http://www.illumina.com) 120 and the relevant PubMed databases (Probe, Database of Genotypes and Phenotypes, and Gene Expression Omnibus DataSets) and found that the COMT Val158Met polymorphism was not included in the platforms commonly used in genome-wide association studies. But since the identification of COMT Val158Met polymorphism, the role of COMT Val158Met in cancers risk has been reported in an increasing number of studies, but the results remained controversial. Some recent meta-analyses studies reported such an association only for single cancer or specific populations. Importantly, several published studies were not included in the previous metaanalysis, and additional original studies with larger sample sizes have been published since then. Hence, the association between the COMT Val158Met polymorphism and the risk of cancer remains unknown. Therefore, meta-analysis can provide a quantitative summary of the available data supporting the association between COMT Val158Met and cancer risk. Compared with some previous meta-analyses, strengths of our meta-analysis include the large sample size and high statistical power of the analysis based on substantial number of cases and controls from differential studies, which minimized selection bias and led to relatively stable risk estimation.
In the current meta-analysis, 99 case-control studies with 43,085 cancer cases and 57,882 control subjects were considered. The results indicated no significant association between COMT Val158Met polymorphism and overall cancer risk in any genetic comparison model tested. In further subgroup analysis by cancer type, COMT Val158Met was significantly associated with an increased risk of bladder cancer and esophageal cancer in some specific genetic models. However, studies on renal, endometrial, lung, liver, ovarian, colon cancers, and other cancer types have suggested null associations. In line with most previous meta-analyses for single cancer, Zhang et al, 111 Du et al 102 and Mao et al 121 have reported that the COMT Val158Met polymorphism may not contribute to the risk of prostate cancer, ovarian cancer, or breast cancer in any of the assessed genetic model. In the subgroup analysis by ethnicity, no significant associations were found in African, Caucasian, and mixed populations. However, the significant association between the COMT Val158Met polymorphism and cancer risk remains to be determined in Asians. The discrepancy in ethnicity could be attributed to the evident difference in the minor allele frequency of Val158Met polymorphism in Asians and Caucasians in our meta-analysis. This genetic polymorphism variance with ethnicity was consistent with those described in a previous study. 8 In addition, stratified analyses by genotyping techniques indicated that studies involving AS-PCR likely acquired significant results in the overall comparison. However, this result should be carefully interpreted because of a relatively small sample size. Moreover, this result should be confirmed by further analysis of additional published studies.
Several limitations should be acknowledged in this meta-analysis. First, only studies in English or Chinese were included in this meta-analysis, which might cause publication bias. Second, the pooled results were based on unadjusted estimates because not all studies had provided adjusted ORs. Even in cases where adjusted ORs were found, they were not adjusted by the same confounders. Hence, a precise analysis should be performed. Third, several factors such as gene-gene or gene-environment interaction may influence gene-disease factor, and the lack of individual data from the included studies limited further evaluation of other potential interactions, as in other genes and environment factors. Finally, cancer is a multifactorial disease resulting from complex interactions among many genetic and environmental factors. Therefore, a single gene or single environmental factor is unlikely to explain cancer susceptibility.
Conclusion
In conclusion, the present meta-analysis suggested that COMT Val158Met polymorphism might not be a risk factor for overall cancer risk, but it might be involved in cancer development at least in some ethnic groups (Asian) or some specific cancer types (bladder and esophageal cancer). Further large-scale and well-designed studies regarding different ethnicities are required to confirm the results of our meta-analysis.
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